PEAK6
VERV

PEAK6’s Verve Therapeutics VERV Stock Holding History

PEAK6’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,500
Closed -$127K – 3666
2024
Q4 		$127K Buy
+22,500
New +$127K ﹤0.01% 2667

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

PEAK6's VERV Position: Q1 2025 in Review

PEAK6 sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 22,500 shares — an estimated $127K sold.

PEAK6 first reported a position in VERV in Q4 2024 and held it in 1 quarter. The position peaked at $127K in Q4 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • PEAK6 reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PEAK6 sold 22,500 Verve Therapeutics shares in Q1 2025, an estimated $127K.
  • PEAK6 first reported a position in Verve Therapeutics in Q4 2024 and held it in 1 quarter.
  • PEAK6's Verve Therapeutics position peaked at $127K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.